NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 11 August 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Peter Selby (Vice Chair) Present for all items
3. Dr Alex Cale Items 1 to 5.2.2
4. Michael Chambers Items 1 to 4.3.2 & 6 to 6.2.2
5. Dr Prithwiraj Das Present for all items
6. Dr David Foreman Present for all items
7. Dr Rob Forsyth Items 6 to 6.2.2
8. Dr Natalie Hallas Present for all items
9. Dr Mudasar Mushtaq Present for all items
10. Dr Richard Nicholas Present for all items
11. Ugochi Nwulu Present for all items
12. Stella O’Brien Present for all items
13. Professor Subhash Pokhrel Present for all items
14. Professor Andrew Renehan Present for all items
15. Professor Matthew Stevenson Present for items 1 to 6.1.3
16. Professor Paul Tappenden Present for all items

NICE staff present

Ross Dent, Associate Director Items 1 to 5.2.2

Jasdeep Hayre, Associate Director Items 6 to 6.2.2

Louise Jafferally, Project Manager Present for all items

Gavin Kenny, Project Manager Items 6 to 6.2.2

Charlie Hewitt, Health Technology Assessment Adviser Items 1 to 4.3.2

Caron Jones, Health Technology Assessment Adviser Items 5 to 5.2.2

Hannah Nicholas, Health Technology Assessment Adviser Items 6 to 6.2.2

Catherine Parker, Health Technology Assessment Analyst Items 1 to 4.3.2

Zain Hussain, Health Technology Assessment Analyst Items 5 to 5.2.2

Anne Murray-Cota, Health Technology Assessment Analyst Items 6 to 6.2.2

Edgar Masanga, Business Analyst, RIA Present for all items

Helen Barnett, Senior Medical Editor Items 1 to 4.3.2

Olivia Havercroft, Senior Medical Editor Items 5 to 5.2.2

Korin Knight, Senior Medical Editor Items 6 to 6.2.2

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment, items

Claire Hawksworth, Technical Analyst, Evidence Generation Items 1 to 4.3.2

Swapna Mistry, Project Manager, Centre for Guidelines Items 1 to 4.1.3

Laura Marsden, Public Involvement Adviser, PIP Items 6 to 6.2.2

Lucinda Evans, Coordinator, Corporate Office Items 1 to 4.1.3, 5 to 5.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Items 1 to 6.1.3

Ismahan Abdullah, Administrator, TA items 6 to 6.2.2

Sophie McHugh, Administrator, COT Items 5 to 5.2.2

Louise Jones, Administrator, TA Items 5 to 6.2.2

Daniel Greenwood, Administrator Items 5 to 5.2.2

External review group representatives present

Marrissa Martyn-St James, School of Health and Related Research (ScHARR)

Items 1 to 4.1.3

Miriam Brazzelli, Aberdeen HTA Group Items 5 to 5.1.3

Corinne Booth, Aberdeen HTA Group Items 5 to 5.1.3

Pim Wetzelaer, Kleijnen Reviews Ltd Items 6 to 6.1.3

Robert Wolff, Kleijnen Reviews Ltd Items 6 to 6.1.3

Clinical & patient experts present

Professor Peter Clark, National Clinical lead for Cancer drugs fund, NHS England, Items 1 to 4.3.2

Dr Duncan Churchill, Consultant in HIV/Genitourinary Medicine, expert nominated by British HIV Association, Items 6 to 6.1.3

Dr Cheryl Gowar, expert nominated by National AIDS Trust (NAT), Items 6 to 6.1.3

Anna Kafkalias, expert, NHS England, Items 6 to 6.1.3

Alex Sparrowhawk, expert nominated by The UK Community Advisory Board (UK-CAB), Items 6 to 6.1.3

Adele Torkington, Pharmacist, expert nominated by HIV Pharmacy Association, Items 6 to 6.1.3

Dr Laura Waters, Chair GU/HIV consultant and HIV & hepatitis lead, expert nominated by British HIV Association (BHIVA), Items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 13 July 2021

### Appraisal of fedratinib for disease-related splenomegaly and symptoms in myelofibrosis (ID1501)

* 1. Part 1 – Open session
     1. The chair welcomed the external review group representative, the National Clinical lead for Cancer drugs fund, members of the public and company representatives from Celgene, a BMS company.
     2. The chair asked all committee members, the national clinical lead for cancer drugs fund, external review group representative and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared a financial interest as he has attended paid advisory boards with Roche and Novartis for treatment in an unrelated area (MS).
* It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* Professor Stephen O’Brien declared that, in his role as a consultant haematologist, he looks after patients with myelofibrosis but had no financial interests to declare.

It was agreed that his declaration would not prevent Professor O’Brien from participating in this section of the meeting.

* Committee member Professor Matthew Stevenson declared a non-financial interest as he is employed by ScHARR. He confirmed he has not been involved in the production or peer review of the ERG report.
* It was agreed that his declaration would not prevent Professor Stevenson from participating in this section of the meeting.
* Committee member Professor Paul Tappenden declared a non-financial interest as he is employed by ScHARR. He confirmed he has not been involved in the production or peer review of the ERG report.
* It was agreed that his declaration would not prevent Professor Tappenden from participating in this section of the meeting.
* No further conflicts were declared for this item
  + 1. The chair led a discussion of the consultation comments presented to the committee.
  1. Part 2a – Closed session (members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (company representatives and external review group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of berotralstat for preventing acute attacks of hereditary angioedema (ID1624)

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed, external review group representatives, members of the public and company representatives from BioCryst Pharmaceuticals.
     2. The chair asked all committee members, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers had declared before the meeting that in 2020 he attended a Biocryst advisory board for this medicine. As a direct financial conflict, it was agreed Michael would not participate in the discussion of this appraisal and he did not attend the meeting.
* No further conflicts were declared for this Item
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 - Closed session (company representatives, external review group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of cabotegravir and rilpivirine for treating HIV-1 (ID3766)

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed the invited clinical and patient experts, NHS Commissioning expert, external review group representatives, members of the public and company representatives from ViiV Healthcare.
     2. The chair asked all committee members, clinical and patient experts, NHS Commissioning expert, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared financial interests as he has attended paid advisory boards with Roche and Novartis for treatment in an unrelated area (MS).
* It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* Committee member Michael Chambers declared financial interest as he has provided consultancy advice to GSK for products in unrelated disease areas, and has co-ordinated a training programme for Roche, which did not involve specific consideration of Roche products.
* It was agreed that his declaration would not prevent Michael from participating in this section of the meeting.
* Nominated expert Dr Duncan Churchill declared financial interest as he has received payment for attending advisory boards and sponsorship to attend conferences, and/or speaker fees from Viiv, Gilead, Janssen and MSD.
* It was agreed that his declaration would not prevent Dr Churchill from providing expert advice to the committee.
* Nominated expert Dr Laura Waters declared financial interest as she has received payment for attending advisory boards and sponsorship to attend conferences, and/or speaker fees from Viiv, Gilead, Janssen and MSD.
* It was agreed that her declaration would not prevent Dr Waters from providing expert advice to the committee.
* Nominated expert Dr Cheryl Gowar declared financial interests as NAT receives financial support from ViiV and other pharmaceuticals for policy research. This grant funding is not related to endorsement of specific medications. NAT also campaigns to improve healthcare and access to medication for all people living with HIV. This does not extend to endorsement of or advocating for specific medications.
* It was agreed that her declarations would not prevent Dr Gowar from providing expert advice to the committee.
* Nominated expert Alex Sparrowhawk declared financial interests as he is the Chair of UK-CAB (HIV treatment advocates network).
* It was agreed that his declaration would not prevent Alex from providing expert advice to the committee.
* No further conflicts were declared for this Item
  + 1. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Natalie Hallas, Dr Robert Forsyth, and Stella O’Brien.
  1. Part 2 - Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 14 September 2021 and will start promptly at 9.30am.